Table 1.
Baseline patient characteristics based on pre-transplantation examination.
| Patients Characteristics | Derivation Set (n = 349) | Validation Set (n = 214) | p-Value |
|---|---|---|---|
| Age, years | 55.7 ± 7.8 | 53.7 ± 7.6 | 0.004 † |
| Sex, Male, (n, %) | 286 (81.1%) | 182 (85.0%) | 0.229 ‡ |
| Maximal Tumor size, cm | 3.0 ± 2.1 | 2.6 ± 2.1 | 0.021 † |
| Tumor number, no. | 1.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.046 |
| AFP, ng/mL | 19.0 (7.1–130.5) | 13.9 (5.5–70.6) | 0.060 |
| PIVKA-II, mAU/mL | 29.0 (15.0–137.5) | 31.5 (19.0–111.8) | 0.171 |
| Portal vein invasion, (n, %) | 44 (12.6%) | 39 (18.2%) | 0.068 ‡ |
| BCLC stage | 40/156/65/33/55 | 21/79/34/26/54 | 0.042 ‡ |
| 0/A/B/C/D, (n, %) | 11.5/44.7/18.6/9.5/15.8 | 9.8/36.9/15.9/12.1/25.2 | |
| Type of HCC | 279/25/0 | 192/20/2 | 0.214 ‡ |
| Nodular/diffuse or infiltrative, (n, %) | 91.8/8.2/0.0 | 89.2/9.3/0.9 | |
| Median follow-up, months | 71.4 (12.8–104.3) | 77.3 (56.0–117.7) | 0.004 |
| Proportion of beyond-MC | 114 (32.7%) | 90 (42.1%) | 0.024 ‡ |
| Portal vein invasion, (n, %) | 44 (38.6%) | 39 (43.3%) | 0.494 ‡ |
| Multinodular HCCs (≥4), (n, %) | 53 (46.5%) | 46 (51.1%) | 0.512 ‡ |
| Large HCCs (>5 cm), (n, %) | 38 (33.3%) | 20 (22.2%) | 0.081 ‡ |
AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; MC, Milan criteria. Note. Data are expressed as n (%), mean ± standard deviation for normally distributed continuous variables, or the median with interquartile range for continuous variables with a skewed distribution. † by student t-test; ‡ by Pearson’s Chi-square; Mann-Whitney test.